Few areas of longevity science have generated more enthusiasm, more commercial activity, and more scientific controversy in the past decade than NAD+ precursor supplementation. Nicotinamide adenine dinucleotide (NAD+) sits at the center of cellular energy metabolism, DNA repair signaling, and the sirtuins—the class of longevity-associated proteins that David Sinclair’s laboratory at Harvard has argued are central to the aging process. NAD+ levels decline with age in most human tissues, and this decline correlates with reduced mitochondrial function, impaired DNA repair, and increased inflammatory signaling. The logical inference—restore NAD+ levels, slow aging—has driven a supplement market now estimated at several billion dollars annually.
The science underlying this inference is real. What has taken longer to establish is which delivery method actually restores NAD+ in target tissues at what cost, what the clinical effects of that restoration are in humans (as opposed to yeast and mice), and what counter-evidence demands consideration before confident protocol recommendations can be made.
NAD+ Biology: Why Precursors Rather Than Direct Supplementation
NAD+ itself cannot be directly supplemented in a way that reaches cells meaningfully. It is a large charged molecule that does not traverse cell membranes, is rapidly degraded in the gastrointestinal tract if taken orally, and cannot enter cells via IV administration in its intact form. Cells synthesize NAD+ via the salvage pathway from precursors, principally nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). A separate de novo synthesis pathway from tryptophan also exists but is quantitatively less significant for supplementation purposes.
The pathway from precursors to NAD+ matters because it determines which tissues are actually reached and at what conversion efficiency. NMN must be converted to NR to cross most cell membranes (via the ectonucleotidase CD73 or the recently identified Slc12a8 transporter in the small intestine), then phosphorylated intracellularly back to NMN and ultimately to NAD+. NR crosses cell membranes more directly, though the specifics of its transporter remain an area of active research.
The NMN Human Trial Landscape Through 2025
NMN’s clinical trial program has matured substantially since 2021. The Washington University study by Yoshino and colleagues, published in Science that year, demonstrated that 250 mg/day NMN supplementation for ten weeks improved muscle insulin sensitivity and increased skeletal muscle NAD+ metabolome in postmenopausal women with prediabetes—the first human trial to demonstrate tissue-level NAD+ enhancement from oral NMN.
Subsequent trials have expanded the picture. A 2022 Japanese clinical trial published in NPJ Aging and Mechanisms of Disease found that 250 mg NMN daily for twelve weeks increased NAD+ levels in peripheral blood mononuclear cells (PBMCs), improved physical performance measures in older adults (sixty-five-plus), and reduced drowsiness. A 2023 trial by Igarashi and colleagues at Keio University using 500 mg NMN daily found significant improvements in gait speed in older adults, a functional outcome with clinical relevance for fall prevention and aging independence.
David Sinclair has been vocal in his personal NMN use and his scientific support for the hypothesis, taking what he has publicly described as one gram daily of NMN along with resveratrol (which he argues enhances sirtuin activation in the presence of increased NAD+). His group’s mouse research has been foundational—2013 Cell paper showing NAD+ restoration via NMN reverted vascular and muscle aging in older mice—but the translation to humans has proceeded more cautiously in the peer-reviewed literature than in his popular science communication.
By 2024-2025, the NMN trial literature has grown to include approximately fifteen completed human studies across a range of doses (100 mg to 1200 mg daily), durations (four to twenty-four weeks), and populations. The pattern across these trials supports blood/PBMC NAD+ elevation at doses of 250 mg and above, with functional benefits in metabolic health, physical performance, and fatigue reduction in populations with room for improvement. The picture in already-healthy young adults is less clear, as their NAD+ levels are less depleted at baseline.
NR: The Earlier Clinical Track Record
NR has the longer human clinical trial history, having been commercialized in 2013 and studied in formal trials since approximately 2016. ChromaDex’s TRU NIAGEN (NR chloride) has been the subject of multiple industry-funded trials that, usefully, included independent academic sites.
The most comprehensive NR trial remains the Elysium Health BASIS study and the subsequent ChromaDex-funded trials showing dose-dependent blood NAD+ increases of 40–90% from NR doses of 300–1000 mg daily. The Brenner and Conze study published in Nature Communications demonstrated that 100–300 mg NR daily safely and significantly elevated NAD+ metabolites in healthy middle-aged adults. A 2019 trial from the University of Colorado found that NR at 1000 mg daily reduced liver NAD+ consumption and improved metabolic markers in older adults.
A notable head-to-head comparison between NMN and NR in terms of NAD+ bioavailability remains lacking as of early 2025. Both compounds appear to elevate blood NAD+ metabolites meaningfully at appropriate doses. Mechanistic differences in tissue distribution—NMN’s potential preferential uptake in the small intestine via Slc12a8, NR’s direct cellular entry—suggest they may deliver NAD+ to different tissue compartments preferentially, but human tissue biopsy studies confirming this are not yet published.
The Conboy Lab Counter-Narrative
The aging field’s most important methodological challenge to the NAD+ longevity hypothesis has come from Irina and Michael Conboy’s laboratory at UC Berkeley. Their 2023 paper in Aging Cell examined whether NR supplementation in old mice produced the anti-aging effects predicted by the NAD+ depletion hypothesis, finding not only that benefits were modest but that elevated NAD+ in old animals paradoxically increased TGF-beta signaling and inflammatory markers in certain tissues.
The Conboy findings do not negate the metabolic and functional benefits of NAD+ precursor supplementation demonstrated in human trials. They do complicate the narrative that NAD+ restoration is universally and straightforwardly anti-aging. The sirtuin activation pathway, in particular, may behave differently depending on systemic inflammatory context—older individuals with high inflammatory burden might respond to NAD+ precursors differently than the relatively healthy older adults studied in most trials.
IV NAD+: The Clinical Protocol
Intravenous NAD+ administration delivers the molecule directly to bloodstream at concentrations far exceeding what oral precursors achieve in blood. IV NAD+ protocols originated in addiction medicine—specifically in the work of William Hitt and the Springfield Wellness Center (Louisiana), which developed IV NAD+ protocols for opioid and alcohol detoxification in the 1960s-70s. The mechanism involves rapid normalization of neuronal NAD+ levels and modulation of the reward pathway.
Contemporary IV NAD+ protocols in longevity medicine typically involve 500–1000 mg infused over four to six hours (slower infusion reduces the chest pressure and flushing that occurs with rapid administration), delivered over three to ten consecutive days, with maintenance infusions monthly thereafter. Blood NAD+ levels following IV administration spike dramatically—ten to twenty times baseline—but return to baseline within approximately seventy-two hours without oral precursor support.
The argument for IV NAD+ over oral supplementation is peak concentration and rapidity: IV delivers NAD+ to all tissues including the brain (with some restrictions at the blood-brain barrier) at concentrations oral precursors cannot match. The argument against is cost (five hundred to one thousand dollars per infusion), time (four to six hours per session), and the lack of RCT-level evidence for IV-specific benefits over oral supplementation.
The most honest synthesis of the 2024-2025 evidence is as follows: oral NMN or NR at 300–1000 mg daily is safe, demonstrably elevates NAD+ metabolites, and produces measurable functional benefits in relevant populations. IV NAD+ produces more dramatic acute NAD+ elevation and may be warranted for individuals seeking rapid neurological effects or managing addiction recovery. The longevity implications of either intervention remain promising but unconfirmed by long-duration human trials. The difference between NMN and NR is probably less important than marketing suggests. What is certain is that the biology underlying these interventions is real, the research trajectory is positive, and the field will look materially different by 2027.
[ QUICK POLL // 60 SECONDS ]